-
2 weeks ago | 
bioxconomy.com | Millie Nelson
The firm’s Series B approach reflects a changing CGT funding climate as they bring a rare disease gene therapy to the clinic. EQT Life Sciences and Sanofi Venture funds co-led the round, with participation from Roche Venture Fund and all other existing investors. SpliceBio said the financing will be used to clinically develop the company’s lead gene therapy candidate, SB-007.
-
3 weeks ago | 
bioxconomy.com | Millie Nelson
Pyx Health, an Arizona-based healthcare technology company focused on addressing loneliness and social isolation, has acquired FarmboxRx, a healthcare food company that delivers customized food boxes for specific health conditions. This merger integrates nutritional support into care pathways by combining Pyx's mentor-driven care navigation model with FarmboxRx's approach of delivering tailored fresh produce.
-
3 weeks ago | 
bioxconomy.com | Millie Nelson
The firm’s launch, built upon more than $90 million raised from investors, aims to pioneer precision neurotherapeutics focused on repairing and advancing synaptic function in central nervous system (CNS) diseases. Zelquistinel Syndeio's lead candidate is advancing through Phase II trials for major depressive disorder (MDD) at nearly 30 US sites. The drug is also preparing to enter biomarker trials targeting synaptic function in Alzheimer's disease.
-
3 weeks ago | 
bioxconomy.com | Millie Nelson
The funding will advance its pipeline of multiple Phase II programs and aims to address critical gaps in reproductive medicine and women’s health. The Phase II programs in question include the firm’s lead candidate RPN-001 (leflutrozole) and RPN-002 (nolasbian). RPN-001 is an oral therapy for male infertility linked to low testosterone and RPN-002 treats adenomyosis, a painful condition of endometrial overgrowth.
-
3 weeks ago | 
bioxconomy.com | Millie Nelson
The Blueprint acquisition gives Sanofi control of Ayvakit, the only approved systemic mastocytosis treatment. The French pharmaceutical giant Sanofi will expand its presence in the immunology space through its $9.1 billion acquisition of Blueprint. Potential milestone payments could push the total value of the deal to $9.5 billion, which represents around 27% over Blueprint’s closing price on May 30.
-
1 month ago | 
bioxconomy.com | Millie Nelson
At LSX World Congress Europe, thought leaders explored diversity's visible and invisible dimensions, sharing insights on creating more inclusive events. A “Catalysts for Change” roundtable deep-dove into diversity equity and inclusion (DEI) across the life sciences space at LSX World Congress Europe in London, UK. The concept of DEI is comprehensive and encompasses both visible and invisible traits. Membersof the roundtable discussed how its definition is multifaceted and goes beyond demographics.
-
1 month ago | 
bioxconomy.com | Millie Nelson
Eli Lilly will expand its pain pipeline through the acquisition of SiteOne, adding Phase II-ready Nav1.8 inhibitor STC-004. While the upfront payment remains undisclosed, Lilly's deal with SiteOne Therapeutics – a private biotech specializing in sodium channel inhibitors for pain and neuronal hyperexcitability disorders – could ultimately reach $1 billion in cash payments.
-
1 month ago | 
bioxconomy.com | Millie Nelson
Sanofi's initial $40 million investment in Vigil has evolved into a complete acquisition, bringing the Alzheimer's drug candidate VG-3927 under its corporate umbrella. The clinical-stage biotech company Vigil used its $40 million investment from Sanofi to drive its R&D plans. Fast forward just shy of one year, the French firm has decided to acquire Vigil for $470 million and will add oral small molecule TREM2 agonist VG-3927 to its portfolio.
-
1 month ago | 
bioxconomy.com | Millie Nelson
Jean-Pierre Latere, CEO of EsoBiotec, reflects on his journey from capital constraint to inking an M&A deal worth up to $1 billion with AstraZeneca. The deal, which has now closed, saw pharma giant AstraZeneca pay cell therapy firm EsoBiotec $425 million upfront and up to $575 million in capital based on specific development and regulatory milestones. However, Latere did not follow the traditional biotech founder’s trajectory.
-
1 month ago | 
bioxconomy.com | Millie Nelson
Having partnered with VC firm Eckuity, digital health firm Huma discusses its two-pronged growth strategy including the acquisition of respiratory health specialist Aluna. The firm has bought California-based remote monitoring and management company Aluna (also known as Knox Medical Diagnostics), for an undisclosed fee. Aluna's spirometers and respiratory monitoring technology will come under Huma's umbrella while adding over 150 US-based health systems and clinic networks to its global footprint.
